Clinical trials: Myocardial Diseases
Coronary Artery Disease
MCG Algorithm Optimization Study in Patients With Coronary Artery Stenosis
This prospective, multicenter study aims to optimize the Magnetocardiography (MCG) algorithm for detecting myocardial ischemia in patients with coronary artery stenosis.
- Trial name
- NCT07888465
- Volunteers
- 165 people
- Sponsor
- AMCG
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Coronary Artery Disease, ST-segment Elevation Myocardial Infarction
Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
The purpose of this study is to prospectively observe the incidence rate of acute kidney injury (AKI), major adverse renal and cardiovascular events (MARCE) in participants who were diagnosed with ST-segment elevation myocardial…
- Trial name
- NCT03671603
- Testing
- Iodixanol
- Where
- 36 sites in China, South Korea
- Volunteers
- 2,755 people
- Sponsor
- GE Healthcare
Obstructive Hypertrophic Cardiomyopathy (oHCM)
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
- Trial name
- NCT07107373
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Stable Angina, Unstable Angina
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or…
- Conditions
- Stable Angina, Unstable Angina, ACS - Acute Coronary Syndrome, STEMI
- Trial name
- eCOBRA (NCT03103620)
- Testing
- COBRA PzF Coronary Stent System
- Where
- 18 sites in France
- Volunteers
- 1,027 people
- Sponsor
- CeloNova BioSciences, Inc.
Coronary Artery Disease
TAXUS PERSEUS Small Vessel
The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo…
- Trial name
- PERSEUS SV (NCT00489541)
- Testing
- Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
- Where
- 28 sites in United States
- Volunteers
- 224 people
- Sponsor
- Boston Scientific Corporation
Acute Coronary Syndromes
An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index…
- Trial name
- TARGET (NCT01061086)
- Where
- 11 sites in Greece
- Volunteers
- 418 people
- Sponsor
- AstraZeneca
ICD, Cardiomyopathy Ischemic
Assessment of Risk Factors for Appropriate ICD (Implantable Cardioverter-defibrillator) Intervention in Patients With Ischemic Cardiomyopathy
Design: PARCADIA is a prospective non-randomized non-interventional multi-center clinical investigation in Europe. Patients with depressed LV (left ventricular) function assessed on local standards, of ischemic origin and on…
- Conditions
- ICD, Cardiomyopathy Ischemic, Primary Prevention
- Trial name
- PARCADIA (NCT04014946)
- Testing
- ICD implantation
- Volunteers
- 200 people
- Sponsor
- Biotronik SE & Co. KG
Sudden Cardiac Death, Ventricular Fibrillation
LifeVest Post-CABG Registry
This is a multi-center prospective registry of patients with an ejection fraction (EF) ≤ 35% following coronary artery bypass graft (CABG) surgery in order to test the hypothesis that wearable defibrillators (WD) will decrease…
- Conditions
- Sudden Cardiac Death, Ventricular Fibrillation, Ventricular Tachycardia, Ventricular Dysfunction
- Trial name
- NCT01448005
- Testing
- wearable defibrillator (LifeVest)
- Where
- 5 sites in United States
- Volunteers
- 69 people
- Sponsor
- Zoll Medical Corporation
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
- Trial name
- HEARTWORK (NCT01065051)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Coronary Artery Disease, Acute Coronary Syndrome
Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment
The objective of GIANT Study is to evaluate the clinical impact of genetic resistance to thienopyridine profile determination (CYP2C19 gene) and the clinical impact of compliance to an adjusted thienopyridine treatment on STEMI…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Genetic Resistance to Clopidogrel, Compliance to Thienopyridine Treatment
- Trial name
- GIANT (NCT01134380)
- Where
- 12 sites in France
- Volunteers
- 1,500 people
- Sponsor
- Biotronik France
Coronary Artery Disease
Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the…
- Trial name
- NCT07397351
- Testing
- Aroxxen
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- Research Institute of Geroprotective Technologies
Coronary Artery Disease
Stereotaxis Computed Tomography (CT) Co-Registration Study
The Stereotaxis Niobe® II Magnetic Navigation System (MNS) is designed to direct and digitally control catheter and guidewire based therapeutic and diagnostic devices along complex trajectories within the heart and coronary…
- Trial name
- NCT00994331
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stereotaxis
Coronary Artery Disease
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System (SDS) in patients with de novo native coronary…
- Trial name
- NCT00231283
- Testing
- CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease, Pain
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease.
- Conditions
- Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
- Trial name
- NCT00832572
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction
Determining the Optimal Cut-off Point of PEA by Corsens Device for Discriminating Between MI and Non-MI Subjects
Acute Myocardial Infarction (MI) is still the leading cause of death in the western world. Early warning (chest pain) signs of an acute MI are often misinterpreted and disregarded.
- Trial name
- NCT02723851
- Testing
- Corsens
- Volunteers
- 76 people
- Sponsor
- Corsens Medical LTD
Acute Coronary Syndrome
A NIS Registry of the Prospective Structured Care In Acute Coronary Syndrome
The purpose of the study is to analyse patient's acceptance and willingness to participate in a Structured Care Program (SCP) over 12 months following hospital discharge after Acute Coronary Syndrome (ACS) index event.
- Trial name
- ProAcor (NCT01490645)
- Where
- 45 sites in Germany
- Volunteers
- 1,006 people
- Sponsor
- AstraZeneca
Coronary Stenosis
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- TALENT (NCT02870140)
- Testing
- SUPRAFLEX, XIENCE
- Where
- 23 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 1,435 people
- Sponsor
- ECRI bv
Coronary Artery Disease
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
- Trial name
- NCT00733460
- Testing
- BFPET
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.